Frazier Life Sciences Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-264,377
| Closed | -$304K | – | 51 |
|
|
2024
Q3 | $304K | Hold |
264,377
| – | – | 0.01% | 52 |
|
|
2024
Q2 | $291K | Hold |
264,377
| – | – | 0.01% | 49 |
|
|
2024
Q1 | $328K | Hold |
264,377
| – | – | 0.01% | 50 |
|
|
2023
Q4 | $278K | Hold |
264,377
| – | – | 0.01% | 49 |
|
|
2023
Q3 | $1.81M | Hold |
264,377
| – | – | 0.12% | 48 |
|
|
2023
Q2 | $2.74M | Hold |
264,377
| – | – | 0.16% | 46 |
|
|
2023
Q1 | $2.14M | Sell |
264,377
-25,812
| -9% | -$209K | 0.15% | 47 |
|
|
2022
Q4 | $4.57M | Sell |
290,189
-118,140
| -29% | -$1.86M | 0.28% | 40 |
|
|
2022
Q3 | $6.43M | Hold |
408,329
| – | – | 0.49% | 35 |
|
|
2022
Q2 | $5.7M | Hold |
408,329
| – | – | 0.54% | 31 |
|
|
2022
Q1 | $7.04M | Buy |
+408,329
| New | +$7.04M | 0.6% | 33 |
|